HFD decreases intermediate-term memory. by Tong Yue (6033305)

“…<p>(A) The survival rate of 10d <i>Canton-S</i> fed with ND or HFD was observed for 7 days. There was no significant decline in the survival rate in flies fed with HFD compared with ND (n = 10 vials, containing 20 flies at each time point). …”

Aripiprazole significantly decreases phosphorylated Src (Y416) levels in dHL-60 cells. by Courtney A. Swain (15170264)

Nineteen SNPs with significant association (<i>P < </i>5 × 10⁻⁸) with risk on minJSW decrease in knee OA. by Mieke L. M. Bentvelzen (21594442)

“…<p>Nineteen SNPs with significant association (<i>P < </i>5 × 10⁻⁸) with risk on minJSW decrease in knee OA.…”

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. by Mieke L. M. Bentvelzen (21594442)

“…The red line represents the significance threshold (<i>P < </i>5 × 10⁻⁸). …”

Does a correlation exist between delayed vaccination and a decreased vaccine confidence? by Virginia Reverte (9046494)

“…Suffering motor/intellectual delay and the obstacles to vaccination process derived from caring for other siblings were associated with delay in second MMR dose. The VCI decreased significantly in first dose group as delay increases but did not change in the second one. …”

Scatter plots of the relationships between age and the proportions of cells which statistically significantly correlated with age. by Arttu Autio-Kimura (20454681)

Subjects:

Scatter plot for the significant Mendelian randomization (MR) association (P < 0.05) between mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects: